NASDAQ:LYEL
Lyell Immunopharma, Inc. Stock News
$2.77
+0.110 (+4.14%)
At Close: May 31, 2024
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
04:05pm, Tuesday, 07'th May 2024
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies fo
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
08:00am, Monday, 06'th May 2024
SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies fo
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
06:25pm, Tuesday, 16'th Apr 2024
Lyell Immunopharma, Inc.'s stock price has risen over 20% YTD and over 45% in the past 12 months. The company focuses on T-cell therapies for solid tumors and has two clinical-stage assets. Lyell has
Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know
01:01pm, Thursday, 07'th Mar 2024
Does Lyell Immunopharma (LYEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
04:30pm, Tuesday, 05'th Mar 2024
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
04:05pm, Wednesday, 28'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies f
Lyell Immunopharma Announces Participation in March Investor Conferences
04:05pm, Monday, 26'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies f
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
04:05pm, Wednesday, 03'rd Jan 2024
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies f
Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL
02:23pm, Friday, 10'th Nov 2023
Lyell Immunopharma results from a phase 1 study using LYL797 for the treatment of relapsed/refractory NSCLC and TNBC patients with ROR1 expression expected in the 1st half of 2024. Results from phase
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
04:05pm, Thursday, 09'th Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies f
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
04:05pm, Tuesday, 07'th Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T‑cell reprogramming company advancing a diverse pipeline of cell therapies
Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical trials in progress Presentations to highlight ne
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform
08:00am, Monday, 11'th Sep 2023
SOUTH SAN FRANCISCO. Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therap
Lyell Immunopharma to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 31'st Aug 2023
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies f
Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data
09:29am, Saturday, 26'th Aug 2023
Lyell is a developer of personalized T-cell therapies for solid tumors, with two programs targeting various types of solid tumors. Their pipeline includes LYL797, a CART cell targeting TNBC and NSCLC,